Department of Surgery, GATA - Ankara/Turkey.
Clinics (Sao Paulo). 2010 Feb;65(2):157-64. doi: 10.1590/S1807-59322010000200007.
The purpose of this study was to investigate the significance of fascin expression in colorectal carcinoma.
This is a retrospective study of 167 consecutive, well-documented cases of primary colorectal adenocarcinoma for which archival material of surgical specimens from primary tumor resections were available. We chose a representative tissue sample block and examined fascin expression by immunohistochemistry using a primary antibody against "fascin". We calculated the "immunohistochemical score (IHS)" of fascin for each case, which was calculated from the multiplication of scores for the percentage of stained cells and the staining intensity.
Fascin immunoreactivity was observed in 59 (35.3%) of all cases with strong reactivity in 24 (14.4%), moderate reactivity in 25 (14.9%) and weak reactivity in 10 (6.0%) cases. Strong/moderate immunoreactivities were mostly observed in invasive fronts of the tumors or in both invasive and other areas. Fascin immunoreactivity scores were significantly higher in tumors with lymph node metastasis (p:0.002) and advanced stage presentation (p:0.007). There was no relation between fascin expression and age, gender, depth of invasion, distant metastasis or histological grade (p>0.05). There was a higher and statistically significant correlation between fascin immunoreactivity in the invasive borders of tumors and lymph node metastasis (r:0.747, p:0.005). In stage III/IV tumors, two-year survival was 92.2% in tumors without fascin immunoreactivity, and only 60.0% in tumors with a fascin IHS>10 (p:0.003).
These findings suggest that fascin is heterogeneously expressed in approximately one third of colorectal carcinomas with a significant association with lymph node metastasis, tumor stage and location. Moreover, these results indicate that fascin may have a role in the lymph node metastasis of colorectal carcinomas.
本研究旨在探讨 fascin 在结直肠癌中的表达意义。
这是一项回顾性研究，纳入了 167 例连续的、有详细记录的原发性结直肠腺癌病例，这些病例均有原发肿瘤切除手术标本的存档材料。我们选择了一个有代表性的组织样本块，并使用针对“fascin”的一抗通过免疫组织化学方法检测 fascin 的表达。我们计算了每个病例的 fascin 的“免疫组织化学评分（IHS）”，该评分是通过染色细胞百分比和染色强度评分的乘积计算得出的。
所有病例中有 59 例（35.3%）观察到 fascin 免疫反应性，其中强反应性 24 例（14.4%）、中度反应性 25 例（14.9%）和弱反应性 10 例（6.0%）。强/中度反应性主要见于肿瘤的侵袭前沿或侵袭和其他区域。淋巴结转移（p：0.002）和晚期表现（p：0.007）的肿瘤中 fascin 免疫反应性评分显著较高。fascin 表达与年龄、性别、浸润深度、远处转移或组织学分级之间无相关性（p>0.05）。肿瘤侵袭边缘的 fascin 免疫反应性与淋巴结转移之间存在更高且具有统计学意义的相关性（r：0.747，p：0.005）。在 III/IV 期肿瘤中，无 fascin 免疫反应性的肿瘤两年生存率为 92.2%，而 fascin IHS>10 的肿瘤仅为 60.0%（p：0.003）。
这些发现表明 fascin 在大约三分之一的结直肠癌中呈异质性表达，与淋巴结转移、肿瘤分期和位置显著相关。此外，这些结果表明 fascin 可能在结直肠癌的淋巴结转移中发挥作用。
